Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

While Blenrep has been granted accelerated approval by the FDA for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody, a ...

GSK (NYSE:GSK) said patients who received its antibody-drug conjugate, Blenrep, as a combination therapy lived nearly three times longer without a relapse compared to the standard of care in ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

The sequence homology is over 95%; PTM and aggregation prediction reports are also available 100% success rate As quick as 3–4 weeks to offer required humanized antibodies Affinity evaluated by ...

The researchers created input data for the deep-learning model using sequences of known antigen binders. This method correctly predicted 90% of the best antibodies in one test with 1,000 ...

Examples of antibody sequences accepted: variable region sequenced from hybridoma, hits (Fab or scFv) selected from display library based method, sequences from single B cell and/or repertoire ...

Poorly performing antibodies have plagued biomedical sciences for decades. Several fresh initiatives hope to change this.

To engineer better proteins, including antibodies, scientists often iteratively mutate the amino acids—the units that are arranged in a sequence to make up proteins—in different positions ...

In a study published in Cell Reports, researchers from Prof. Idit Shachar's laboratory at the Weizmann Institute of Science ...